Skip to main content
SpringerLink
Log in

Isradipine Dose-Confirmation Study in Filipino Patients with Mild to Moderate Hypertension

  • Section 3: Future Clinical Trends
  • Published:
Drugs Aims and scope Submit manuscript

Summary

The effective and well tolerated dose of isradipine was determined in 130 Filipino patients with mild to moderate essential hypertension in a multicentre study with a 2-week placebo pretreatment period followed by an 8-week active treatment period.

37 male and 93 female patients (mean age 51 years, mean weight 59.9kg) participated in the study. Average systolic/diastolic blood pressure on admission was 163.8/103.7mm Hg.

Results showed isradipine normalised sitting diastolic blood pressures in 109 of 130 (83.8%) patients. 71 patients (54.6%) were receiving isradipine 1.25mg twice daily while 38 patients (29.2%) required a dose of 2.5nig twice daily.

A drop of ⩾ 10mm Hg in sitting diastolic blood pressure was achieved in 71 patients (54.6%) administered isradipine 1.25mg twice daily and 44 patients (33.8%) on isradipine 2.5mg twice daily. Heart rate was not significantly changed with either dosage. Drug-related adverse effects were only transient in duration and mild to moderate in severity. No patient discontinued treatment because of these effects.

This study provides confirmatory evidence of the clinical efficacy and tolerability of a daily dose of ⩽ 5mg isradipine in Filipino patients with mild to moderate hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Fleckenstein A. Specific pharmacology of calcium in myocardium, cardiac pacemakers and vascular smooth muscle. American Review of Pharmaceutical Toxicology 17: 149–166, 1977

    Article  CAS  Google Scholar 

  • Hansson L. Isradipine — a calcium antagonist specifically developed for the treatment of hypertension. Proceedings of a symposium: Lomir, a new first line treatment for hypertension, USSR, 22 Nov, 1988

  • Hansson L, Robertson JIS. Is hypertension treated adequately? Drugs 34(Suppl. 3): 1–6, 1987

    Article  PubMed  Google Scholar 

  • Hof R. Analysis of peripheral vascular actions of the new calcium antagonist isradipine. American Journal of Medicine 84: 18–25, 1988

    Article  Google Scholar 

  • Messerli F, Oren S, Grossman E. Effects of calcium channel blockers on systemic hemodynamics in hypertension. American Journal of Medicine 84: 8–11, 1988

    Article  Google Scholar 

  • Nelson E, Pool J, Taylor A. Antihypertensive activity of isradipine in humans: a new dihydropyridine calcium antagonist. Clinical Pharmacology and Therapeutics 40: 694–697, 1986

    Article  PubMed  CAS  Google Scholar 

  • Pool P, Seagren S, Selel A. Isradipine in the treatment of angina pectoris. American Journal of Medicine 84: 62–66, 1988

    Article  Google Scholar 

  • Schoenberger J. New approaches to a first-line treatment of hypertension. American Journal of Medicine 84: 26–31, 1988

    Article  Google Scholar 

  • Singh B., The mechanism of action of calcium antagonists relative to their clinical applications. British Journal of Clinical Pharmacology 21: 109S–121S, 1986

    Article  PubMed  CAS  Google Scholar 

  • Weinstein D, Heider J. Antiatherogenic properties of calcium antagonists. American Journal of Cardiology 59: 163B–172B, 1987

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Philippine General Hospital, Manila, Philippines

    Ramon F. Abarquez Jr

  2. Philippine Heart Center, Manila, Philippines

    Esperanza I. Cabral

  3. Pablo S. Torres Memorial Hospital, Manila, Philippines

    Ernesto P. Namin

  4. St Luke’s Heart Institute, Manila, Philippines

    Homobono B. Calleja

  5. Cardinal Santos Memorial Hospital, Manila, Philippines

    Camilo I. Porciuncula

  6. University of the East Ramon Magsaysay Memorial Medical Centre, Manila, Philippines

    Romeo A. Divinagracia

  7. Santo Tomas University Hospital, Manila, Philippines

    Roberto V. Anastacio

  8. Manila Doctors’ Hospital, Manila, Philippines

    Rafael R. Castillo

Authors
  1. Ramon F. Abarquez Jr
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Esperanza I. Cabral
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ernesto P. Namin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Homobono B. Calleja
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Camilo I. Porciuncula
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Romeo A. Divinagracia
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Roberto V. Anastacio
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Rafael R. Castillo
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Abarquez, R.F., Cabral, E.I., Namin, E.P. et al. Isradipine Dose-Confirmation Study in Filipino Patients with Mild to Moderate Hypertension. Drugs 40 (Suppl 2), 33–37 (1990). https://doi.org/10.2165/00003495-199000402-00010

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-199000402-00010

Keywords

Search

Navigation